Strategic Pricing, and Reimbursement Solutions for Accelerated Patient Access
In partnership with our clients, we develop comprehensive pricing, and reimbursement strategies that align with both clinical value and commercial goals. Our expert teams work closely with stakeholders at global, European and national levels to navigate the complexities of today’s rapidly evolving market access landscape, addressing regulatory requirements, payer expectations, and healthcare system constraints to accelerate patient access to innovative therapies.
Leveraging our deep expertise in Health Technology Assessment (HTA) we support companies in developing rigorous, evidence-based assessments that meet the standards of health authorities, aligned with their specificity. The submission of high-quality dossiers aims to support informed decision-making, demonstrating the clinical and economic value of products to payers, regulators, and other key decision-makers. Our goal is to ensure that your products achieve optimal pricing and reimbursement outcomes, leading to successful market entry and sustained patient access.
Your trusted partner in market access, pricing and HTA strategy
- Comprehensive Pricing and Reimbursement Strategies: We collaborate with clients to develop pricing, and reimbursement strategies that seamlessly align clinical value with commercial objectives, ensuring a strong foundation for success.
- Navigating Market Access Complexities: Our expert teams work alongside stakeholders to manage regulatory requirements, payer expectations, and healthcare system constraints, accelerating patient access to innovative therapies in an evolving landscape.
- Health Technology Assessment (HTA) Expertise: We create rigorous, evidence-based assessments that meet health authoritities’ standards and specificities and support the submission of high-quality dossiers to optimize pricing and reimbursement outcomes for successful market entry.
PLG's extensive expertise, combined with its flexibility and adaptability, ensured not only the correct definition of the product’s value but above all its recognition by the regulatory authorities and the best possible patient access.
Head of Value and Access